CEO: Wendel Barr.
Revenue: $42.1 million in 2010; $41.3 million in 2009.
No. of local employees: 220.
Investors: Gryphon Investors, San Francisco.
Year founded: 1995.
Company description: A full-service contract research organization serving biotechnology, medical device and pharmaceutical companies. Clinical trial expertise is focused on therapies related to oncology, the central nervous system, cardiovascular disease and ophthalmology.
Key factors for success: Synteract emphasizes customer service, with a 90 percent rate of repeat business.
Carlsbad-based Synteract Inc...